We demonstrated that EGFRHIGH tumor subcluster was distinctly elevated in the pembrolizumab-treated group and exhibited significantly higher level of lactate producing biomarkers including LDHA and SLC16A3 compared to the combination group in both HNSCC and LUSC PDX. The gene discussed is SLC16A3; the disease is neoplasm.